Global MarketsJuly 28 at 09:55 AM

GSK (GSK LN) is guiding to more than 31% margin in 2026

StockNow breaking-news AI analysis

GSK is targeting >31% margins in 2026 through a £1.9B cost-saving plan. Strong Q2 results and a doubled R&D pipeline aim to offset the 2028 dolutegravir patent cliff.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLY Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy